The global health community is locked in an urgent race against time as an Ebola epidemic continues to surge across Africa. In early June 2026, major reporting from the Center for Infectious Disease Research and Policy (CIDRAP) and The New York Times revealed that the Coalition for Epidemic Preparedness Innovations (CEPI) has fast-tracked three experimental Ebola vaccine candidates.

The sudden urgency stems from a tricky biological shift. The current outbreak in the Democratic Republic of the Congo (DRC) and Uganda is being driven by a rare Ebola strain called Bundibugyo. While the medical world already has highly effective vaccines for the more common Zaire strain, the Bundibugyo virus features different surface molecules. Because of these structural changes, existing vaccines simply cannot recognize it, leaving healthcare workers without an approved shot or targeted treatment for this specific version.

With suspected cases climbing past 1,000 and roughly 250 deaths reported, global health organizations are stepping up by investing tens of millions of dollars into rapid clinical trials. The hope is to avoid a “full-blown public health crisis,” ABC News reports.

How the experimental Ebola vaccines work

The newly funded candidates are relying on a variety of innovative platforms to prevent the spread of pathogens. According to the BBC, these candidates come from the University of Oxford, Moderna and IAVI. The purpose is to train the immune system to fight the virus.

The main structural barrier is the virus’s surface glycoprotein, according to the NIH. This is the chemical key it employs. The virus then attaches to healthy human cells using the key and enters them. Vaccination regulates the body’s response. It activates the immune system, producing certain antibodies. These antibodies directly bind to the glycoproteins and block infection.

• The mRNA platform: Backed by over $60 million in CEPI funding, Reuters reports that Moderna is using the same mRNA technology that underpinned its COVID-19 vaccine. This is a shot that carries genetic instructions to human cells. It encourages them to safely produce non-toxic copies of the Bundibugyo glycoprotein. This enables the immune system to test out developing similar countermeasures.
• The viral vector platforms: The University of Oxford is using its chimpanzee adenovirus (ChAdOx1) vector. The Serum Institute of India can rapidly scale this platform. In the interim, IAVI is modifying a non-pathogenic virus, vesicular stomatitis virus. This strategy provided 100 percent protection in preliminary animal testing of Bundibugyo countermeasures.

Common side effects

These fast-tracked candidate vaccines are still in the early stages of human clinical trials (Phase 1), so scientists are diligently documenting their side-effect profiles. Health experts anticipate their initial physical responses will be quite similar to those of existing licensed viral vector and mRNA systems.

The most frequently reported adverse effects include redness, swelling and pain at the injection site. This is usually located in the arm. This is a totally normal sign of the reaction. It indicates that the body’s immune cells are active against the vaccine components. In this way, they begin producing protective antibodies.

As the immune system mobilizes defense mechanisms, patients often have systemic effects. These are mild-to-moderate reactions that occur within 24-48 hours. Common side effects are low-grade fevers, mild muscle aches, joint pain and chills, headaches and fatigue. Usually, these symptoms resolve on their own.

Rare or serious side effects

Large-scale safety profiles for the new vaccines in Bundibugyo are still being determined, and clinical trials are being closely monitored for serious but uncommon side effects of the licensed Ebola vaccine.

Rare side effects, according to the World Health Organization, may include severe allergic reactions. Anaphylaxis is a common reaction that occurs within minutes of injection. These cases are emergency cases and should be treated immediately. Furthermore, a handful of viral vector platforms are associated with rare cases of transient, painful joint swelling.

These arthritic or skin rashes may last for a couple of weeks after immunizations. These formulations have fast-track approval pathways, so research is conducted with great care. They look for any unforeseen abnormal neurological or cardiovascular findings in human trials.

What to do if you notice symptoms

“In practice, effective symptom management will be a critical factor for people who may take part in future trials. And for healthcare professionals who are asked to administer early-access vaccines,” stresses Dr. Justus Rabach, MD. “This way, the patient’s overall safety is guaranteed. If the side effects are mild and expected, such as a low-grade fever or muscle aches, treatment usually involves resting, staying well hydrated and using over-the-counter pain relievers as necessary. Get medical help as soon as possible if you experience a sudden-onset rash, facial swelling or throat swelling.”

It’s also important to be aware of signs such as trouble breathing, sudden high fever or unusual neurological symptoms like tingling. Adverse events in an active outbreak area are directly reported. Inform the medical team on board the clinical trial that you are sending these data. This is for proper safety data logging for the ongoing study.

As regional containment lines shift, domestic disease surveillance is tightening across neighboring nations. In June 2026, a situation developed regarding a makeshift quarantine unit. The United States proposed a 50-bed Ebola quarantine facility at Laikipia Air Base in Kenya. However, the Kenyan High Court quickly suspended its construction and opening, as reported by CBS News. This suspension followed intense local protests and legal challenges over biosecurity risks. If you are traveling through or near areas with active epidemics, stay informed. Knowing local quarantine mandates and nearby testing centers is vital to your safety. It also supports global efforts to control disease.

Alternatives

Since a targeted vaccine is still months away from widespread deployment, frontline healthcare workers are relying on a mix of rigorous infection control and cutting-edge experimental treatments. According to the CDC, the absolute gold standard for stopping Ebola in its tracks remains strict isolation protocols paired with the universal use of personal protective equipment (PPE).

For patients currently battling active infections, a World Health Organization (WHO) panel has recommended fast-tracking two experimental monoclonal antibody treatments, maftimivab and MBP-134, which are now moving into immediate clinical trials. Think of these therapies as laboratory-engineered proteins that mimic the body’s natural defenses. By tightly latching onto the virus, they neutralize the infection and provide a vital line of defense for patients who do not yet have vaccine protection.

Who was patient 0 for Ebola?

According to historical records from the Fogarty International Center and the World Health Organization (WHO), the global introduction to one of the world’s most lethal pathogens began with a 44-year-old schoolteacher named Mabalo Lokela. In late August 1976, Lokela returned to his remote home village of Yambuku, Zaire (now the Democratic Republic of the Congo), after touring the northern region near the Central African Republic. Shortly after his return, he presented with a sudden, debilitating illness characterized by a raging fever and severe symptoms. Because the disease was entirely unknown at the time, his condition was initially misdiagnosed and treated as malaria.

The tragedy quickly escalated due to the scarce resources of the local mission hospital. Because medical supplies were incredibly limited in this rural area, unsterilized needles and syringes were routinely reused across patients, unknowingly creating a perfect vector for the highly contagious virus.

This practice rapidly amplified the infection throughout the clinic, devastating families and frontline healthcare workers alike. As the mysterious and fatal hemorrhagic fever claimed dozens of lives, it drew the urgent attention of international health authorities. The subsequent investigation into this horrific chain of events ultimately allowed scientists to isolate a novel pathogen, which they named the Ebola virus after the nearby Ebola River, marking a grim but pivotal milestone in modern virology.

How many people have died of Ebola?

Cumulatively, across all documented species and outbreaks since its initial discovery in 1976, more than 11,00 people have tragically died from Ebola disease globally. The overwhelming majority of these fatalities occurred during the catastrophic 2014–2016 West Africa epidemic caused by the Zaire strain, says the WHO.

That outbreak alone resulted in an estimated 28,600 cases and over 11,300 deaths. These figures are based on historical data from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

“With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease,” Richard Hatchett, MD, CEO of CEPI, said in a press release. “CEPI’s urgent funding and support aims to advance safe, effective vaccines to help control this epidemic.”

Bottom line

The expanding 2026 African Ebola outbreak is driven by the little-known Bundibugyo strain. This genetically distinct virus renders existing commercial vaccines completely ineffective. In response, international groups have fast-tracked three candidate vaccines. These are from Oxford, Moderna and IAVI, which have entered clinical testing. Experimental monoclonal antibody treatments are also being evaluated. Until these countermeasures pass human safety trials, standard public health tools remain essential. Meticulous hospital isolation, contact tracing and the expansion of local testing capacity remain our only line of defense against this severe epidemic threat.

Frequently Asked Questions

Which country got Ebola first?

The Democratic Republic of the Congo (formerly Zaire) and South Sudan (formerly Sudan) experienced the very first simultaneous outbreaks of the virus in 1976.

What is the FDA-approved vaccine for Ebola?

The only FDA-approved vaccine for Ebola disease is Ervebo, which provides 100 percent protection specifically against the Zaire strain but does not protect against the current Bundibugyo epidemic.

Citations

Soucheray S. Center for Infectious Disease Research and Policy. CIDRAP. Published June 2026. Accessed June 3, 2026. https://www.cidrap.umn.edu/ebola/three-ebola-vaccine-candidates-fast-tracked-african-outbreak-continues

Zimmer C. As Ebola Spreads, Scientists Race to Find Vaccines and Treatments. The New York Times. Published 2026. https://www.nytimes.com/2026/06/01/science/ebola-vaccines-treatments.html

Gretsky W, Kekatos M. Ebola outbreak spreading in Africa is “likely far worse” than official figures suggest: IRC. ABC News. Published June 2026. https://abcnews.com/Health/ebola-outbreak-spreading-africa-worse-official-figures-suggest/story?id=133492636

Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177-182. doi:https://doi.org/10.1038/nature07082

Gallagher J. Three Ebola vaccines in development amid growing outbreak fears. BBC. https://www.bbc.com/news/articles/cn8pw93929wo. Published June 1, 2026.

Rigby J, Sunny ME, Steenhuysen J. Moderna and other groups get $60 million to develop Ebola vaccine. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-partners-with-global-health-coalition-develop-bundibugyo-ebola-vaccine-2026-06-01/. Published June 1, 2026.

World Health Organization. Ebola Disease. Who.int. Published April 24, 2025. https://www.who.int/news-room/fact-sheets/detail/ebola-disease

Inocencio R. Kenyan court blocks opening of U.S. Ebola quarantine center on air base. Cbsnews.com. Published May 29, 2026. Accessed June 3, 2026. https://www.cbsnews.com/news/ebola-us-kenya-court-blocks-american-quarantine-center-laikipia-air-base/

CDC. Clinical Guidance for Ebola Disease. Ebola. Published June 24, 2024. https://www.cdc.gov/ebola/hcp/clinical-guidance/index.html

World Health Organization. Experts convened by the WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus. Who.int. Published May 28, 2026. https://www.who.int/news/item/28-05-2026-experts-convened-by-who-advise-on-candidate-treatments-and-vaccines-for-ebola-disease-caused-by-bundibugyo-virus

Fogarty International Center. Analysis of 1976 Ebola outbreak holds lessons relevant today – Fogarty International Center @ NIH. Nih.gov. Published 2016. https://www.fic.nih.gov/News/Pages/2016-ebola-outbreak-1976-lessons-relevant.aspx

World Health Organization. Ebola Outbreak 2014-2016 – West Africa. www.who.int. Published 2025. https://www.who.int/emergencies/situations/ebola-outbreak-2014-2016-West-Africa